- Corvus Pharmaceuticals (CRVS, Financial) will present new interim data from its Phase 1 trial of soquelitinib for atopic dermatitis at the SID 2025 Annual Meeting.
- The presentations, including both oral and poster sessions, will occur from May 8-10, 2025, in San Diego, CA.
- Corvus will outline details on this trial data during its first quarter 2025 business update conference call on May 8, 2025.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical firm focused on ITK inhibition, is set to unveil new interim findings from its Phase 1 clinical trial of soquelitinib. The drug is being evaluated for treating moderate to severe atopic dermatitis. This data, derived from Cohorts 1-3 of the randomized, double-blind, placebo-controlled trial, will be showcased at the Society for Investigative Dermatology (SID) 2025 Annual Meeting scheduled for May 7-10 in San Diego, CA.
Dr. Albert S. Chiou from Stanford University Medical Center will spearhead the presentation of results through both an oral presentation and a poster session. The presentations are titled "Selective Soquelitinib, a selective ITK inhibitor demonstrates activity in atopic dermatitis phase 1 clinical trial by a novel mechanism of action," and will occur from May 8-10, 2025.
These critical findings will also be highlighted in Corvus' first quarter 2025 business update conference call. The call is planned for May 8, 2025, at 4:30 pm ET / 1:30 pm PT, allowing investors and stakeholders to gain further insights into the progress of the clinical trial.
